Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double blind, randomised, 3-arm parallel group, multicentre, 8-week, phase III study to assess antihypertensive efficacy and safety of the combination of candesartan cilexetil (CC)/HCT [hydrochlorothiazide] 32/12.5mg and 32/25mg vs. CC 32mg alone in patients with inadequate BP [blood pressure] control on monotherapy with CC 32mg

Next Previous
Trial Profile

A double blind, randomised, 3-arm parallel group, multicentre, 8-week, phase III study to assess antihypertensive efficacy and safety of the combination of candesartan cilexetil (CC)/HCT [hydrochlorothiazide] 32/12.5mg and 32/25mg vs. CC 32mg alone in patients with inadequate BP [blood pressure] control on monotherapy with CC 32mg

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Candesartan cilexetil; Hydrochlorothiazide
  • Indications Essential hypertension
  • Focus Therapeutic Use

Most Recent Events

  • 05 Apr 2008 The expected completion date for this trial is now .
  • 04 Apr 2008 New trial record.
  • 20 Mar 2008 Biomarkers information updated

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top